期刊文献+

HPLC法测定瑞戈非尼原料药中的有关物质 被引量:3

Determination of Related Substances in Regorafenib by HPLC
下载PDF
导出
摘要 目的:建立测定瑞戈非尼原料药中有关物质的方法。方法:采用高效液相色谱法。色谱柱为WatersAtlantisT3C18,流动相为0.1%三氟乙酸-乙腈(梯度洗脱),流速为1.0ml/min,检测波长为232nm,柱温为35℃,进样量为10μl。结果:AFP-PMA脲(杂质A)、FP-二甲基吡啶甲酰胺(杂质B)、3,4-双-CTF-氨基甲酰胺基-PMA(杂质C)与主成分瑞戈非尼及其他未知杂质均能达到很好的分离;杂质A、B、C和瑞戈非尼检测质量浓度线性范围分别为0.511~5.108μg/ml(r=0.9999)、0.287~2.869μg/ml(r=0.9995)、0.360~3.604μg/ml(r=0.9999)和1.444~14.442μg/ml(r=0.9998);检测限分别为0.052、0.022、0.084和0.071μg/ml;精密度、稳定性、重复性试验的RSD<3%;杂质A、B、C加样回收率分别为102.7%~106.3%、98.2%~102.9%、98.6%~104.3%,RSD分别为1.09%、1.83%、1.57%(n=9)。结论:该方法灵敏、快速、准确、可靠,可用于瑞戈非尼原料药中有关物质的测定。 OBJECTIVE:To establish a method for the determination of related substances in regorafenib. METHODS:Gradientelution HPLC was performed on the column of Waters Atlantis T3 C18 with mobile phase A of 0.1% Trifluoroacetic acid solutionand B of acetonitrile(gradient elution)at a flow rate of 1.0 ml/min,the detection wavelength was 232 nm and column temperaturewas 35 ℃,injection volume was 10 μl. RESULTS:AFP-PMA urease(impurity A),FP- dimethyl pyridine carboxamide(impurityB),3,4-bis-CTF-aminoformamido-PMA(impurity C),regorafenib and other impurities were well separated;the linear range was0.511-5.108 μg/ml for impurity A(r=0.999 9),0.287-2.869 μg/ml for impurity B(r=0.999 5),0.360-3.604 μg/ml for impurity C(r=0.999 9)and 1.444-14.442 μg/ml for regorafenib(r=0.999 8);the detection limit were 0.052,0.022,0.084 and 0.071 μg/ml,respectively;RSDs of precision,stability and reproducibility tests were lower than 3%;recoveries of impurity A,B and C were102.7%-106.3%(RSD=1.09%,n=9),98.2%-102.9%(RSD=1.83%,n=9)and 98.6%-104.3%(RSD=1.57%,n=9). CONCLUSIONS:The method is sensitive,rapid,accurate and reliable,and can be used for the determination of related substances inregorafenib.
作者 滕文荃 TENG Wenquan(Chinese Medicine Hospital In Juxian,Shandong Juxian 276599,China)
机构地区 莒县中医医院
出处 《中国药房》 CAS 北大核心 2016年第24期3431-3434,共4页 China Pharmacy
关键词 瑞戈非尼 高效液相色谱法 有关物质 Regorafenib HPLC Related substance
  • 相关文献

参考文献10

  • 1李进.新型口服多激酶抑制剂瑞戈非尼治疗癌症的研究进展[J].临床肿瘤学杂志,2014,19(5):385-390. 被引量:16
  • 2Grothey A,Sobrero AF,Siena S,et al. Results of a phaseⅢ randomized, double-blind, placebo-controlled,multicenter trial (CORRECT) of regorafenib plus bestsupportive care(BSC)versus placebo plus BSC in patients(pts) with metastatic colorectal cancer (mCRC)who have progressed after standard therapies[J]. J ClinOncol,2012,30(Suppl 4):255.
  • 3EMEA. Regorafenib[EB/OL].(2007-03-26)[2015-04-26]. http://www.ema.europa.eu/ema/.
  • 4U.S. Food and Drug Administration. Regorafenib[EB/OL].(2006-06-28)[2015-03-27]. http://www.fda.gov/.
  • 5Grothey A,Van Cutsem E,Sobrero A,et al. Regorafenibmonotherapy for previously treated metastatic colorectalcancer(CORRECT):an international,multicentre,randomised,placebo-controlled,phase 3 trial[J]. Lancet,2013,381(9 863):303.
  • 6Pal D,De T,Baral A,et al. Regorafenib(STIVARGA):a new option in the treatment of patients with metastaticcolorectal cancer(CRC)[J]. J Pharm Pharm Sci,2013,5(3):6.
  • 7Ji WP,Zhang QW,Hu LF. Development of a simple LCMSassay for determination of regorafenib in rat plasmaand its application to a pharmacokinetic study[J]. Lat AmJ Pharm,2014,33(4):607.
  • 8Hafner FT ,Werner D,Kaiser M. Determination of regorafenib(BAY 73-4506)and its major human metabolitesBAY 75-7495(M-2)and BAY 81-8752(M-5)in human plasma by stable-isotope dilution liquid chromatographytandem mass spectrometry[J]. Bioanalysis,2014,6(14):1 923.
  • 9van Erp NP,de Wit D,Guchelaar HJ,et al. A validatedassay for the simultaneous quantification of six tyrosinekinase inhibitors and two active metabolites in human serumusing liquid chromatography coupled with tandemmass spectrometry[J]. J Chromatogr B Analyt TechnolBiomed Life Sci,2013,937:33.
  • 10Heinz WJ,Kahle K,Helle-Beyersdorf A,et al. High-performanceliquid chromatographic method for the determinationof sorafenib in human serum and peritoneal fluid[J]. Cancer Chemother Pharmacol. 2011,68(1):239.

二级参考文献28

  • 1Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib ( BAY 73- 4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity[J]. Int J Cancer,2011,129( 1 ) :245-255.
  • 2Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis [ J ]. Cancer Res, 2004,64 (19) :7099-7109.
  • 3Dhillon AS, Hagan S, Rath O, et al. MAP kinase signalling path- ways in cancer[J]. Oncogene, 2007,26(22) :3279-3290.
  • 4Strumberg D, Schultheis B. Regorafenib for cancer [ J ]. Expert Opin Investig Drugs, 2012, 21(6) :879-889.
  • 5Bayer Healthcare Pharmaceuticals. Stivarga (regorafenib) from ba- yer healthcare and onyx [ EB/OL ].2012 [ 2013-11-20 ]. http ://la- beling, bayerhealthcare, com/html/products/pi/Stivarga_PI.pdf.
  • 6Mross K, Frost A, Steinbild S, et al. A phase I dose escalation study of regorafenib ( BAY 73-4506) , an inhibitor of ancogenic, angiogenic and stromal kinases, in patients with advanced solid tumors[J] .Clin Cancer Res, 2012,18(9) :2658-2667.
  • 7Strumberg D, Scheulen ME, Schultheis B, et al. Regorafenib ( BAY 73-4506) in advanced colorectal cancer: a phase I study [ J ] .Sr J Cancer, 2012,106( 11 ) : 1722-1727.
  • 8Schuhheis B, Folprecht G, Kuhlmann J, et al. Phase I study of regorafenib sequentially administered with either FOLFOX or FOLFIRI in patients with first-/second line colorectal cancer[ J]. J Clin Oncol, 2011,29 (Suppl) : a3585.
  • 9Bayer Healthcare Pharmaceuticals. First line treatment of meta- static colorectal cancer with mFOLFOX 6 in combination with re- gorafenib [ EB/OL ]. 2011 [ 2013-11-20 ]. http ://clinicahrial. gov/show/NCT01289821.
  • 10UNC Lineberger Comprehensive Cancer Center. Regorafenib + FOLFIRI versus placebo+FOLFIRI as 2nd line Tx in metastatic calorectal cancer [ EB/OL ]. 2011 [ 2013-11-20 ]. http ://clinical- trials, gov/show/NCT01298570.

共引文献15

同被引文献5

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部